Last10K.com

Paratek Pharmaceuticals, Inc. (PRTK) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

Paratek Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1178711 Ticker: PRTK
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2018
Feb. 28, 2019
Jun. 30, 2018
Document And Entity Information [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2018  
Document Fiscal Year Focus2018  
Document Fiscal Period FocusFY  
Trading SymbolPRTK  
Entity Registrant NamePARATEK PHARMACEUTICALS, INC.  
Entity Central Index Key0001178711  
Current Fiscal Year End Date--12-31  
Entity Well-known Seasoned IssuerNo  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Entity Filer CategoryAccelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
Entity Shell Companyfalse  
Entity Common Stock, Shares Outstanding 32,415,977 
Entity Public Float  $ 293,668,914

View differences made from one year to another to evaluate Paratek Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Paratek Pharmaceuticals, Inc..

Continue

Assess how Paratek Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Paratek Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Other
Filter Subcategory:
All
Expense
Product
Cash Flow
Shares
Other
Inside Paratek Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Stockholders' Equity
401(K) Savings Plan
401(K) Savings Plan - Additional Information (Detail)
Accrued Expenses
Accrued Expenses (Tables)
Accrued Expenses - Schedule Of Accrued Expenses (Detail)
Cash And Cash Equivalents And Marketable Securities
Cash And Cash Equivalents And Marketable Securities (Tables)
Cash And Cash Equivalents And Marketable Securities - Additional Information (Detail)
Cash And Cash Equivalents And Marketable Securities - Summary Of Available For Sale Securities (Detail)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Schedule Of Future Minimum Operating Lease Obligations (Detail)
Common Stock
Common Stock (Tables)
Common Stock - Additional Information (Detail)
Common Stock - Warrants Fair Value Assumption (Detail)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Detail)
Fair Value Measurements - Roll Forward Of Fair Value Of Contingent Obligations (Detail)
Fair Value Measurements - Schedule Of Financial Assets And Liabilities Measured At Fair Value (Detail)
Fixed Assets, Net
Fixed Assets, Net (Tables)
Fixed Assets, Net - Additional Information (Detail)
Fixed Assets, Net - Schedule Of Fixed Assets (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Schedule Of (Loss) Income Before Income Taxes (Detail)
Income Taxes - Schedule Of Components Of Income Tax (Benefit) Expense (Detail)
Income Taxes - Schedule Of Deferred Tax Assets And Liabilities (Detail)
Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation (Detail)
Intangible Assets, Net
Intangible Assets, Net - Additional Information (Detail)
License And Collaboration Agreements
License And Collaboration Agreements - Additional Information (Detail)
Long-Term Debt
Long-Term Debt (Tables)
Long-Term Debt - Additional Information (Detail)
Long-Term Debt - Schedule Of Future Principal Payments (Detail)
Long-Term Debt - Summary Of Debt (Detail)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Antidilutive Shares Excluded From Computation Of Diluted Net Income (Loss) Per Share (Detail)
Net Loss Per Share - Computation Of Basic And Diluted Net Loss Per Share Available To Common Stockholders (Detail)
Organization
Organization - Additional Information (Detail)
Preferred Stock
Preferred Stock - Additional Information (Detail)
Quarterly Results (Unaudited)
Quarterly Results (Unaudited) (Tables)
Quarterly Results (Unaudited) - Schedule Of Quarterly Results (Details)
Restricted Cash
Restricted Cash - Additional Information (Detail)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - 2006 Plan - Additional Information (Detail)
Stock-Based Compensation - 2014 Plan - Additional Information (Detail)
Stock-Based Compensation - 2015 Plan - Additional Information (Detail)
Stock-Based Compensation - 2017 Inducement Plan - Additional Information (Detail)
Stock-Based Compensation - Additional Information (Detail)
Stock-Based Compensation - Employee Stock Purchase Plan - Additional Information (Detail)
Stock-Based Compensation - Restricted Stock - Additional Information (Detail)
Stock-Based Compensation - Schedule Of Share-Based Compensation, Common Stock, Shares Reserved For Future Issuance (Detail)
Stock-Based Compensation - Schedule Of Share-Based Compensation, Restricted Stock Unit, Activity (Detail)
Stock-Based Compensation - Schedule Of Share-Based Compensation, Stock Options, Activity (Detail)
Stock-Based Compensation - Schedule Of Share-Based Payment Award, Stock Options, Weighted-Average Valuation Assumptions (Detail)
Stock-Based Compensation - Stock Based Compensation Expense - Additional Information (Detail)
Stock-Based Compensation - Summary Of Stock-Based Compensation Expense Included In Company's Consolidated Statements Of Operations (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Schedule Of Estimated Useful Lives Of Fixed Assets (Detail)
Summary Of Significant Accounting Policies - Summary Of Reconciliation Of Cash, Cash Equivalents, And Restricted Cash Reported Within Condensed Consolidated Statement Of Cash Flows (Detail)
Ticker: PRTK
CIK: 1178711
Form Type: 10-K Annual Report
Accession Number: 0001564590-19-006315
Submitted to the SEC: Tue Mar 05 2019 12:34:40 PM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/prtk/0001564590-19-006315.htm